National Institutes of Health

Description

Data from clinical studies of metformin in a variety of patient populations suggest that it may have other effects, besides being an antihyperglycemic agent, which warrant further attention in translational aging research. The objective of this FOA is to support research projects (R01), including small-scale physiologic studies in humans or secondary analyses of data and/or stored biospecimens from controlled clinical intervention studies, to increase our understanding of the clinical translational potential of metformin to delay deleterious aging changes or to extend healthy human life span. This includes identification of specific populations particularly likely to benefit from treatment, and/or obtaining information on metformins human physiologic and cellular effects that would be useful in identifying novel molecular targets.

Who can apply

• State governments
• County governments
• City or township governments
• Special district governments
• Independent school districts
• Public and State controlled institutions of higher education
• Native American tribal governments (Federally recognized)
• Public housing authorities / Indian housing authorities
• Native American tribal organizations (other than Federally recognized)
• Nonprofits with 501(c)(3) status (other than higher education)
• Nonprofits without 501(c)(3) status (other than higher education)
• Private institutions of higher education
• For-profit organizations other than small businesses
• Small businesses
• Others

Contact

NIH OER Webmaster<br/>FBOWebmaster@OD.NIH.GOV<br/>
FBOWebmaster@OD.NIH.GOV